Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3D Med Diagnosis Completes a $40 Million Initial Funding for Cancer Diagnostics

publication date: Jan 6, 2020

3D Med Diagnosis, a recent diagnostics spin-off from 3D Medicines, raised $40 million in its debut funding. 3D Medicines was established in 2010 to concentrate on the three D's cancer care: diagnostics, drugs and data. 3D Med Diagnosis owns the company's diagnostics portfolio that offers next-gen sequencing for early-stage cancer detection and precision medicine diagnosis. Its cancer diagnostics include histology genomic tests, ctDNA liquid biopsies and an exosome liquid biopsy. The funding was led by China Resources Pharmaceutical Industry Investment Fund. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital